海翔药业(002099) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥528,463,890.64, a decrease of 16.65% compared to ¥634,047,833.60 in the same period last year[7] - Net profit attributable to shareholders was ¥32,593,338.56, down 22.58% from ¥42,101,946.61 year-on-year[7] - Total operating revenue for Q1 2024 was $528.46 million, a decrease of 16.66% from $634.05 million in the same period last year[37] - Net profit for Q1 2024 was $32.10 million, down 23.4% compared to $41.85 million in Q1 2023[41] - Total comprehensive income attributable to the parent company was ¥32,593,338.56, down from ¥42,101,946.61 in the previous period, representing a decrease of approximately 22.5%[43] Cash Flow - The net cash flow from operating activities was ¥28,489,229.96, representing a significant decline of 82.13% from ¥159,451,304.75 in the previous year[7] - Cash inflow from operating activities totaled ¥440,566,222.35, down 11.4% from ¥497,507,810.56 in the previous period[44] - Cash outflow from operating activities increased to ¥412,076,992.39, compared to ¥338,056,505.81 in the previous period, marking a rise of 21.9%[44] - Net cash flow from investing activities was -¥58,747,912.25, a decline from a positive cash flow of ¥81,685,962.84 in the previous period[46] - Cash inflow from financing activities increased to ¥1,175,600,000.00, up from ¥966,107,488.00 in the previous period, reflecting a growth of 21.6%[46] - Cash outflow from financing activities rose to ¥938,615,931.61, compared to ¥362,399,978.71 in the previous period, indicating an increase of 159.2%[46] - The ending balance of cash and cash equivalents was ¥1,459,324,838.28, down from ¥1,869,798,598.82 in the previous period, a decrease of approximately 22%[46] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,650,432,164.42, an increase of 1.73% from ¥7,520,092,953.12 at the end of the previous year[7] - Total liabilities rose to $2.11 billion, compared to $1.92 billion in the previous year, indicating a growth of 10.5%[36] - The company's equity attributable to shareholders decreased by 1.16% to ¥5,541,569,876.91 from ¥5,606,352,298.36[7] - The company maintained a stable equity position with total equity at $5.54 billion, slightly down from $5.61 billion[36] Shareholder Information - Total number of common shareholders at the end of the reporting period is 30,172[18] - Zhejiang Donggang Industrial Co., Ltd. holds 32.37% of shares, totaling 523,982,587 shares[22] - Wang Yunfu, a natural person, holds 7.34% of shares, totaling 118,800,000 shares, with 38,000,000 shares pledged[22] - As of March 31, 2024, the company has repurchased 21,874,798 shares, accounting for 1.3514% of total share capital[27] - The total amount for the share repurchase plan is between RMB 150 million and RMB 300 million, with a maximum repurchase price of RMB 8.92 per share[26] - The chairman, Wang Yangchao, has increased his holdings by 696,500 shares, accounting for 0.0430% of total shares[26] Operational Metrics - The basic and diluted earnings per share remained unchanged at ¥0.02[7] - Non-recurring gains and losses totaled -¥663,358.00, primarily due to foreign exchange hedging losses[8] - The company reported a significant increase in prepayments by 74.96%, amounting to ¥38,986,801.14 compared to ¥22,283,130.66 in the previous year[13] - The company experienced a 92.63% reduction in trading financial liabilities, decreasing to ¥2,682,000.00 from ¥36,370,389.61[13] - Accounts receivable increased to RMB 477,138,467.57 from RMB 424,703,017.66[29] - Inventory decreased to RMB 636,368,872.33 from RMB 702,270,769.40[29] - The company reported a significant increase in research and development expenses, totaling $30.01 million, compared to $31.04 million in the previous year[37] - Investment income showed a loss of $6.03 million, contrasting with a gain of $20.09 million in the prior year[41] Strategic Initiatives - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[39] - The company plans to continue its share repurchase based on market conditions within the specified period[27] Audit Information - The company did not undergo an audit for the first quarter report[48]